Cullinan Therapeutics, Inc. income statement

In fiscal 2022, Cullinan Therapeutics, Inc. reported revenue of $0, down 100.0% on the year before and net income of $111m, or $2.38 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Cullinan Therapeutics, Inc.: income statement, annual
Fiscal year	2020Dec 2020	2021Dec 2021	2022Dec 2022
Revenue	0	19	0
Research and development	43	58	92
General and administrative	17	29	40
Operating income	−60	−68	145
Income before tax	—	−67	151
Income tax	—	0	42
Net income	−52	−66	111
Diluted EPS	−$2.60	−$1.52	$2.38
Diluted shares (average)	20m	43m	47m
EBITDA	−60	−68	145

US$ millions unless shown otherwise. Fiscal quarters.

Cullinan Therapeutics, Inc.: income statement, quarterly
Quarter	2021 Q1Mar 2021	2021 Q2Jun 2021	2021 Q3Sept 2021	2021 Q4Dec 2021	2022 Q1Mar 2022	2022 Q2Jun 2022	2022 Q3Sept 2022	2022 Q4Dec 2022
Revenue	19	0	0	0	0	0	0	0
Research and development	12	12	13	21	25	26	20	21
General and administrative	5	5	6	13	8	11	10	11
Operating income	1	−17	−18	−34	−33	240	−30	−33
Income before tax	1	−16	−18	−34	−32	240	−27	−29
Income tax	0	0	0	0	−20	66	−3	−2
Net income	−0	−16	−17	−33	−12	175	−25	−27
Diluted EPS	$0.00	−$0.36	−$0.40	−$0.76	−$0.27	$3.77	−$0.54	−$0.58
EBITDA	1	−17	−18	−34	−33	240	−30	−33

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Cullinan Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Cullinan Therapeutics, Inc.